FDA Approves Jardiance for the Treatment of Type 2 Diabetes in Children 10 Years and Older
Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to decrease blood sugar together with diet and exercise in children 10 years and older with type 2 diabetes. Jardiance is not indicated for type 1 diabetic patients. In these patients, it may raise their risk of diabetic ketoacidosis. Jardiance should not be used to enhance glycemic control in type 2 diabetes patients with an eGFR less than 30 mL/min/1.73 m2. Based on its method of action, Jardiance is unlikely to be effective in this scenario....
